It produces weight-loss and diabetes drugs Wegovy and Ozempic and saw its shares rise exponentially as demand soared. But as competition grows in the sector — from the U.S.' Eli Lilly in particular — some investors are questioning which company will come out on top. Soros Fund Management, for instance, the family office of George Soros, slashed its stake in Novo Nordisk according to filings published last week. 'Getting a handle on supply' There's a key difference between Novo Nordisk and its U.S. rival, according to Evan Seigerman, BMO Capital Markets biotech analyst.